

Dried blood spot microsampling: A semi-quantitative 4D-Lipidomics approach utilizing MetaboScape for enhanced lipid profiling.

Lipid profiling from biofluids, such as plasma or serum, derived from phlebotomy has been investigated extensively. The use of dried blood spot (DBS) microsampling has been gaining popularity due to its minimal invasiveness and potential for self-sampling. This enables the possibility of outside the clinic sampling and also high-frequency metabolic profiling which can cater to large-scale population-wide research.

Abstract

Here, we demonstrated the potential use of DBS microsampling for 4D-Lipidomics[™] profiling using timsTOF Pro with VIP-HESI. By leveraging real-time data quality monitoring during acquisition, potential issues can be promptly identified and addressed, ensuring optimal data collection. Lipid identification using MetaboScape[®]'s rule-based annotation complemented by Kendrick mass defect plot enhanced confidence in annotation. Additionally, the incorporation of internal standards allowed for semi-quantification of measured lipids within a single acquisition, providing a deeper understanding of lipid concentration variations across different individuals.

Introduction

Dried blood spot microsampling (DBS) is slowly gaining traction in clinical settings as a minimally invasive alternative to venipuncture, using a simple fingerprick and disposable lancet to deposit blood droplets onto a paper substrate. Compared to traditional venous phlebotomy, which is invasive and requires trained personnel, microsampling is self-administrable, and has since been adapted for analyzing diverse biological matrices, including plasma, saliva,

Jayden Lee Roberts^{1,2}, Monique J. Ryan^{1,2}, Luke Whiley^{1,2}, Melvin Gay³, Vimalnath Nambiar^{1,2}, Elaine Holmes^{1,2,4}, Jeremy K. Nicholson^{1,2,5,6}, Julien Wist^{1,2,7}, Nicola Gray^{1,2}, Nathan G. Lawler^{1,2}; ¹Australian National Phenome Centre, Health Futures Institute, Harry Perkins Institute, Murdoch University, 5 Robin Warren Drive, Murdoch, WA 6150, Australia; ²Centre for Computational and Systems Medicine, Health Futures Institute, Harry Perkins Institute, Murdoch University, 5 Robin Warren Drive, Murdoch, WA 6150, Australia; ³Bruker Pty Ltd., Preston, VIC 3072, Australia; ⁴Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, U.K.; ⁵Department of Cardiology, Fiona Stanley Hospital, Medical School, University of Western Australia, Murdoch, WA 6150, Australia; ⁶Institute of Global Health Innovation, Faculty of Medicine, Imperial College London, Level 1, Faculty Building, South Kensington, London SW7 2NA, U.K.; ⁷Chemistry Department, Universidad del Valle, Melendez 76001 Cali, Colombia. Keywords: 4D-Lipidomics, dried blood spot, microsampling, semi-quantative, timsTOF, MetaboScape, ion mobility urine, and breast milk [1]. While this technique has been employed in routine measurement of targeted metabolites, with the most well-known application being newborn screening for phenylketonuria, DBS could be extended to other biomarkers of metabolic health such as lipids. Lipids are among the most functionally versatile, structurally diverse, and physiologically complex biomolecules. They are increasingly recognized for their role in chronic disease development due to their involvement in energy storage, cell signaling, enzyme regulation, and the maintenance of homeostasis [2].

Mass spectrometry (MS)-based workflows have been extensively employed in the field of lipidomics to characterise lipid profiles and understand biological functions in biofluids. Advancements in high-resolution MS instruments together with Trapped Ion Mobility Spectrometry (TIMS-HRMS) has enabled these in-depth studies to be carried out with minute samples volumes (<10 μ L) or even from single cells [3]. The complexity of the lipidome in biological samples is exemplified by a myriad of isobaric lipids, which LC-TIMS-HRMS provides another analytical dimension ("4D") for the elucidation of isobaric compounds based on their structural configuration which is not possible by traditional LC-MS methods.

Herein, we describe a 4D-Lipidomics workflow to evaluate the applicability of in-depth analysis of the whole blood lipidome collected on a DBS substrate, together with MetaboScape 2025 for successful identification and quantitation of these lipids using a microsampling approach.

Methods

Briefly, 10 μ L of capillary blood was sampled from healthy control and diabetic individuals (n = 17 participants in each group) using a commercial microsampling device (Capitainer®, Solna, Sweden)[4]. The DBS samples were extracted with 150 μ L of 80% IPA containing quantitative labeled internal standards (Avanti EquiSPLASH LIPIDOMIX; 1 μ g/mL), before undergoing a 10 min vortex mix, 5 min sonication, 20 min protein precipitation at -20°C, and 10 min centrifugation at 14,000 x g (4°C). 4D UHPLC-TIMS-HRMS analysis was performed across two ionization modes: positive vacuum insulated probe heated electrospray ionization mode (VIP-HESI+) and negative mode (VIP-HESI–). Pooled quality control (PQC) samples were created by combining the DBS extracts to avoid adsorption issues from extracting multiple DBS.

UHPLC-TIMS-HRMS analyses were conducted as described in Table 1 using a UHPLC connected to a timsTOF Pro system equipped with a VIP-HESI source. Real-time data quality monitoring during acquisition was performed using TASQ[®] 2025 (Bruker) with real-time quality control (RTQC).

The resulting data was processed with MetaboScape 2025 for non-targeted profiling using T-ReX[®] 4D algorithm where MetaboScape combines common adducts and isotopes belonging to the same compound into unique features in the feature table. Processed positive and negative mode data were merged into a single feature table for annotation using the rule-based lipid annotation based on the Lipidomics Standards Initiative guidelines [5] and measured CCS of lipid species were matched with the prediction by CCS-Predict Pro. Finally, the annotated lipids were also semi-quantitated with spiked internal standards (ISTD) using MetaboScape 2025.

Results and Discussions

Data quality checks

Data quality in global lipidomic profiling is crucial for biomarker discovery and systems biology studies. However, data quality is frequently checked only after the whole sample set is acquired. This could lead to the loss of precious samples if an issue occurred during the acquisition process.

Herein, we utilise "RealTime QC" (RTQC) to monitor the acquisition process in real-time. Briefly, a processing method using Target Analysis for Screening and Quantitation software (TASQ) is applied to target compounds of interest, such as ISTD or endogenous metabolites. These compounds are then automatically monitored after every run and plotted in RTQC for ease Table 1. MS acquisition parameters in both positive and negative ionization.

Table 2.	LC	para	me	ters
----------	----	------	----	------

MS	timsTOF Pro		LC	Waters Acquity				
Source	VIP-HESI source		Column	Waters BEH C18 (100 x 2.1 mm, 1.7 µm)				
	End Plate Offset	500 V	Column	60°C				
	Capillary	4500 V	Oven Temp.					
	Nebulizer	2.0 bar	Mobile	A: Water/acetonitrile/isopropanol (50/30/20)				
	Dry Gas	8.0 L/min	phase	+ 10 mM amr	nonium acetate			
	Dry Temp	230°C		B: Water/acetonitrile/isopropanol (1/9/90)				
	Probe Gas Temp	400°C (+), 450°C (-)	Dumm	+ TO MIVI ammonium acetate				
	Probe Gas Flow	4.0 L/min	Pump	Seal wash	Isopropanol / water			
Acquisition mode	TIMS-PASEF		Gradiant	Time o [main]		9/ D		
lonization	Positive and Negative		Gradient			% B		
Tims parameters	Ramp time	100 ms		0.0	0.40	10		
	Mobility range	0.55 – 1.90 1/K ₀		2.7	0.40	45		
	ICC Target Intensity	5.0 M		2.8	0.40	53		
Transfer	Scan range	100 – 1350 <i>m/z</i>		8	0.40	60		
parameters	Funnel 1 RF	250 Vpp		8.1	0.40	80		
	Funnel 2 RF	200 Vpp		11.5	0.40	80		
	Multipole RF	200 Vpp		12	0.40	100		
	Collision Energy	ision Energy 10 eV		13	0.40	10		
	Collision RF	450 V		15	0.40	10		
	Quadrupole Low mass	60 <i>m/z</i>	Autosampler	Temperature	8°C			
	Transfer Time 50 µs			Injection volume	5 µl			
	Pre Pulse Storage	3 µs		Wash solvent A	IPA / water (10% / 90%)			
	MS/MS Collision Energy	20-50 eV		Wash solvent B	Isopropanol (100	%)		
Calibration	Automatic internal mass sodium formate and Agil concentration Tunemix	calibration using ent ESI-L low						



Figure 1. Real-time QC visualization of the whole dataset.

In this exemplar using ISTD 18:1(d7)-LPC, a sample was highlighted (in red) with the missing ISTD, which was later identified due to issues during the sample extraction process.

of visualization (Figure 1). Plots such as intensity, and differences between measured and exact values—such as mass-to-charge ($\Delta m/z$), retention time (ΔRT), and CCS ($\Delta 1/K_0$)—can be customized to display the required information. Outliers within the runs are also automatically highlighted in RTQC (i.e. 18:1(d7)-LPC) to indicate samples or instrument issues for further intervention by the user.

Lipid annotation

Lipid species were annotated with MetaboScape's rule-based annotation using precursor *m/z*, isotopic pattern, characteristic MS/MS spectra and measured CCS as an additional quantifier based on MetaboScape's CCS-Predict Pro. Specifically, the target list spans 4 lipid classes including glycerolipids, glycerophospholipids, sphingolipids, and sterol lipids, across 25 subclasses.

A merged 4D-Kendrick mass defect (KMD) plot was used to visualize the lipid distribution of combined positive and negative ionization datasets. KMD is based on the diagnostic structure feature of the lipid fatty acyl chains (CH₂) to organize structurally related lipid subclasses. Further curation of lipid outliers were also readily identified using the outlier function in MetaboScape where annotated lipid outliers based on CCS or RT were highlighted in the KMD plot. A total of 357 unique lipids were annotated in DBS, shown in Figure 2.



Figure 2. Merged KMD plot of DBS lipids detected in both positive and negative ionization.

internal standards																 Figure 3. 30 using inter 	nal	standard	tion of i s (A).	ipias
Aethod: EquiSPLASH	4	~ >	c Inte	ernal standa	rds config	guration										In this exem	plar	r (B). PC 30	6:3 is ani	notated
10			RT	Folerance:	0.10	r	min													
Version: 1.0 Version: L ×			Dilu	Dilution Factor: 1												and assigne	and assigned a "Compound class" (red			
Owner: User, Demo	0	2	L N	ame		Neutral Fo	ormula	RT [K	n (onc. Conc	Compound	d class				box) by Met	aho	Scane usi	na rule-h	ased
escription:			PC	5		CapD7HarN	VaO toP	5.55 [4+H]+	.00 µg/m	Glyceroph	nospholipid	ds > Glyceropho	sphoglycerols > Diacy	Iglycerophospho	box, by mot		ooupo uon	ing rulo c	aoou
			PI			C42D7H78N	NO ₁₃ P	5.40 [4+H]+	.00 µg/m	Glyceroph	nospholipid	ds > Glyceropho	sphoinositols > Diacyl	glycerophosphoi	annotation.	This	s lipid is the	en furthe	er
			PS			CapD2HeeN	NaO ₁₀ P	5.50 [4+H]+	.00 µg/m	Glyceroph	nospholipio	ds > Glyceropho	sphoserines > Diacylg	lycerophosphose		/ II			
			TO			Cs1D7HasC	06	11.67 [4+NH4]+	.00 µg/m	. Glycerolipi	ids > Trira	adylglycerols > T	riacylglycerols		quantitated	(yeii	u (xoa woi	sing its	
			DO	3		C36D7H61C	Ds .	8.92 [4+NH4]+	.00 µg/m	. Glycerolipi	iids > Dira	dyiglycerols > D	acylglycerols		- respective s	nike		C 33.1-d	7)
-			- M	6		C21D2H330	24	3.00 [A+NIUA1+	.00 µg/m	Storel Lini	ids > Mor	noradyiglycerols	> Monoacylglycerols		- respective s	hive	50 10 ID (F	0 00.1-0	
			- CE	4		CuD-H-N	1.O.P	6.82 [A+HI+	.00 µg/m	Sobingolin	nide > Pho	on a cholestero	ds > Ceramide phose	hocholines (sphir	within the s	ame	e sample.		
			Ce	er.		CarD+HasN	10.	7.32 [4+H]+	.00 µg/m	Sphingolip	pids > Cer	amides > N-acv	sphingosines (ceramic	des) and N-acylsr					
			PC			C ₄ ,D ₂ H ₂₀ N	NO.P	7.40 (4+H1+	.00 ug/m	Glyceroph	ospholipie	ds > Glyceropho	sphocholines > Diacvl	alvcerophosphoc					
B	III Feat	ure Table											_				ŧ.	8 8 8 8 8 °		
B	III Feat	ure Table			••••••					T <	filter rules>		Name	~ +	X Name		10	** ***		
B	Teat	RT [CCS	Mob mS	igma 🔺 /	∆CCS [%]	Δm/z [ppm]	Δm/z (mD	 a) m/z meas. 753 61269 	T < M meas. 752 60540	filter rules>	MS/MS	Name Name	 + Molecular Fo 	Name Annotations ▼	Internal Standard	ÂQ	DBS_MS-AI-ULI D	BS_MS-AI-ULI E	
8	Feat	RT [7.32 2.91	CCS 289.3 235.8	Mob mS 1.419 1.148	igma 🔺 J co	∆CCS [%]	∆m/z [ppm]	Δm/z (mD	a] m/z meas. 753.61268 529.39963	T < M meas. 752.60540 528.39236	filter rules>	MS/MS	Name Name PC LPC	 Molecular Fo C41D7H73NO8P C4D1H47NO3P 	K Name Annotations ▼ ●	Internal Standard O iacylglycerophosphocholines Monoacyldlycerophosphocholines	ÂQ	DBS_MS-AI-ULL D 1.000	BS_MS-AI-ULI E	DBS_MS-AI-U
8	1 2 3	RT [7.32 2.91 8.84	CCS 289.3 235.8 295.3	Mob mS 1.419 1.148 1.448	igma • 2 00 0.9	∆CCS [%]	∆m/z [ppm] -0.922	Δm/z (mE	a] m/z meas. 753.61268 529.39963 33 762.60003	T < M meas. 752.60540 528.39236 761.59297	filter rules> lons ± ° ± ° ± °	MS/MS dia dia	Name PC LPC PC 34:0	 Molecular Fo C₄₁D₇H₇₃NO₈P C₂₆D₇H₄₅NO₇P C₁₅H₆₇NO₈P 	Name Annotations ▼ Image: Constraint of the second sec	Internal Standard © Diacylglycerophosphocholines © Monoacylglycerophosphocholines Diacyldycerophosphocholines	AQ	DBS_MS-AI-ULL_D 1.000 1.000 3.116	BS_MS-AI-ULI E 1.000 1.000 3.188	DBS_MS-AI-U 1, 1, 2,
6	1 2 3 4	RT [7.32 2.91 8.84 7.38	CCS 289.3 235.8 295.3 293.6	Mob mS 1.419 1.148 1.448 1.441	igma • 4 00 0.9 1.0	ΔCCS [%] 1.1 0.6	Δm/z [ppm] -0.922 -0.699	Δm/z [mE -0.7 -0.5	a] m/z meas. 753.61268 529.39963 33 762.60003 49 784.58453	T < M meas. 752.60540 528.39236 761.59297 783.57703	filter rules>	MS/MS Ju Ju Ju	Name PC LPC PC 34:0 PC 36:3	 Molecular Fo C₄1D7H73NO8P C₂₆D7H45NO7P C₄₂H₅₄NO3P C₄₄H₅₂NO8P C₄₄H₅₂NO8P 	K Name Annotations ▼ ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● <	Internal Standard © Diacydglycerophosphocholines © Monoacydglycerophosphocholines Diacydglycerophosphocholines Diacydglycerophosphocholines	AQ	DBS_MS-AI-ULL_D 1.000 1.000 3.116 2.809	BS_MS-AI-ULI E 1.000 1.000 3.188 3.024	DBS_MS-AI-L 1.0 2.9 3.0
6	1 2 3 4 5	RT [7.32 2.91 8.84 7.38 8.78	CCS 289.3 235.8 295.3 293.6 298.1	Mob mS 1.419 1.148 1.448 1.441 1.441	igma • 4 00 0.9 1.0 1.2	ΔCCS [%] 1.1 0.6 1.0	Δm/z [ppm] -0.922 -0.699 -1.084	Δm/z (mE -0.7 -0.5 -0.8	a) m/z meas. 753.61260 529.39963 33 762.60003 49 784.58453 37 772.62063	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335	filter rules>	MS/MS dis dis dis dis dis	Name PC LPC PC 34:0 PC 36:3 PC 0-36:2	 Molecular Fo C41D;H73N04P C26D;H45N07P C44B62N08P C44B62N08P C44B62N08P C44B62N07P 	Name Annotations ▼ Image: Constraint of the second sec	Internal Standard © Diacy[glycerophosphocholines ØMonacy[glycerophosphocholines Diacy[glycerophosphocholines Diacy[glycerophosphocholines	AQ	DBS_MS-AI-ULL D 1.000 1.000 3.116 2.809 0.000	BS_MS-AI-ULL. E 1.000 1.000 3.188 3.024 40196.512	DBS_MS-AI-L 1, 1, 2, 3, 33931.
₿	1 2 3 4 5 6	RT [7.32 2.91 8.84 7.38 8.78 2.81	CCS 289.3 235.8 295.3 293.6 298.1 232.1	Mob mS 1.419 1.148 1.448 1.441 1.462 1.128	igma • 4 00 0.9 1.0 1.2 1.4	ΔCCS [%] 1.1 0.6 1.0 0.0	Δm/z [ppm] -0.922 -0.699 -1.084 0.965	Δm/z [mE -0.7 -0.5 -0.8 0.4	a] m/z meas. 753.61266 529.39963 33 762.60003 49 784.58453 37 772.62063 79 496.34025	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240	filter rules>	MS/MS dus dus dus dus dus dus	Name PC LPC PC 34:0 PC 36:3 PC 0-36:2 LPC 16:0	 Molecular Fo C41D;H73N04P C26D;H43N07P C44H62N08P C44H62N08P C44H62N07P C24H62N07P C24H62N07P 	Name Annotations V C C C C C C C C C C C C C C C C C C C	Internal Standard O lacy[djycerophosphocholines O Monoacy[djycerophosphocholines Diacy[djycerophosphocholines Monoacy[djycerophosphocholines	AQ	DBS_MS-AI-ULLD 1.000 1.000 3.116 2.809 0.000 1.899	BS_MS-AI-ULL E 1.000 1.000 3.188 3.024 40196.512 1.877	BS_MS-AI-L 1.0 1.0 2.5 3.0 33931.2 1.8
6	1 Feat 1 2 3 4 5 6 7	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46	CCS 289.3 235.8 295.3 293.6 298.1 232.1 232.1 239.9	Mob mS 1.419 1.148 1.448 1.441 1.462 1.128 1.167	igma 4 4 00 0.9 1.0 1.2 1.4 1.5	ΔCCS [%] 1.1 0.6 1.0 0.0 0.1	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3	a) m/z meas. 753.61260 529.39963 303 762.60003 49 784.58453 7 772.62063 79 496.34025 59 524.37144	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240 523.36380	filter rules>	MS/MS Ju Ju Ju Ju Ju Ju Ju Ju Ju	Name PC LPC PC 34:0 PC 36:3 PC 0-36:2 LPC 16:0 LPC 18:0	 Molecular Fo C41D7H3NO8P C42D7H3NO8P C42H94NO8P C44H92NO8P C44H92NO3P C44H92N03P C44H92N03P	Name Annotations ▼ Image: Constraint of the second sec	nternal Standard o Diacydglycerophosphocholines o Monacydglycerophosphocholines Diacydglycerophosphocholines Diacydglycerophosphocholines Monacydglycerophosphocholines	AQ	DBS_MS-AI-ULLD 1.000 1.000 3.116 2.809 0.000 1.899 0.825	Image Image <th< td=""><td>DES_MS-AI-L 1.1 1.1 1.2 3.3 33931.1 1.4 0.4</td></th<>	DES_MS-AI-L 1.1 1.1 1.2 3.3 33931.1 1.4 0.4
6	1 1 2 3 4 5 6 7 7 8	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44	CCS 289.3 235.8 295.3 293.6 298.1 232.1 239.9 229.1	Mob mS 1.419 1.148 1.448 1.441 1.462 1.128 1.167 1.115	igma • 4 0.9 1.0 1.2 1.4 1.5 1.6	ΔCCS [%] 1.1 0.6 1.0 0.0 0.1 -1.1	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 0.4	a) m/z meas. 753.61260 529.39963 303 762.60003 49 784.58453 77 772.62063 79 496.34025 59 524.37144 16 520.34018	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240 523.36380 519.33264	filter rules>	MS/MS da da da da da da da da da da da	Name PC LPC PC 34:0 PC 34:0 PC 0-36:2 LPC 16:0 LPC 18:0	 Molecular Fo C41D7H73N08P C42D7H33N07P C42H84N05P C44H82N03P C44H84N07P C24H30N07P C24H30N07P C24H30N07P C26H32N07P 	Name Annotations V O O O O O O O O O O O O O O O O O O O	nternal Standard O Diacytaycerophosphocholines O Monocytaycerophosphocholines Diacytaycerophosphocholines Diacytaycerophosphocholines Monoacytaycerophosphocholines Monoacytaycerophosphocholines	AQ	200 201 201 201 201 201 201 201 201 201	BS_MS-AI-ULL_ 1.000 1.000 3.188 3.024 40196.512 1.877 0.937 0.622	DES_MS-AI-L 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.
6	1 Feat 1 2 3 4 5 6 7 7 8 9	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14	CCS 289.3 235.8 295.3 293.6 298.1 232.1 239.9 229.1 293.8	Mob mS 1.419 1.148 1.448 1.441 1.462 1.128 1.167 1.115 1.441	igma A 4 00 0.9 1.0 1.2 1.4 1.5 1.6 1.7	ACCS (%) 1.1 0.6 1.0 0.0 0.1 -1.1 0.6	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799 -1.113	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.8	a) m/z meas. 753.61268 529.39963 3762.60003 49 784.58453 37 772.62063 79 496.34025 5 524.37144 16 520.34018 73 784.58421	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240 523.36380 519.33264 783.57698	Ions 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	MS/MS das das das das das das das das das das	Name PC LPC PC 34:0 PC 36:3 PC 0-36:2 LPC 16:0 LPC 18:0 LPC 18:2 PC 36:3	Molecular Fo C41DH13NO4P C3DH13NO4P C3DH13NO4P C41H43NO4P C41H43NO4P C41H43NO4P C41H43NO4P C41H43NO4P C41H43NO4P C41H43NO4P C41H43NO4P C41H43NO4P	Name Annotations Image: Constraint of the second	De Internal Standard O Diacylgly:erophosphocholines Diacylgly:erophosphocholines Diacylgly:erophosphocholines Monoacylgly:erophosphocholines Monoacylgly:erophosphocholines Monoacylgly:erophosphocholines	AQ	Image: Second	MS MS-AI-ULL E 1.000 1.000 3.188 3.024 40196.512 1.877 0.937 0.622 3.168	DES_MS-AI-L 1.0 1.0 3.3 3.3931.2 1.6 0.6 0.7 2.5
6	1 Feat 1 2 3 4 5 6 7 7 8 9 9 10	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 2.65	CCS 289.3 235.8 295.3 293.6 298.1 232.1 239.9 229.1 293.8 232.8	Mob mS 1.419 1.148 1.448 1.441 1.462 1.128 1.167 1.115 1.441 1.131	igma 4 2 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1	LCCS (%) 1.1 0.6 1.0 0.0 0.1 -1.1 0.6 0.3	Δm/z [ppm] -0.922 -0.699 -1.084 0.704 0.709 -1.113 -0.127	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.8 -0.0	a) m/z meas. 753.61260 529.39963 37 762.60003 49 784.58453 37 772.62063 59 524.37144 520.34018 73 784.58421 36 496.33970	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240 519.33264 783.57690 495.33249	Ions Ions 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	MS/MS Iks Iks Iks Iks Iks Iks Iks Iks Iks	Name PC LPC PC 34:0 PC 36:3 PC 06:3: LPC 16:0 LPC 18:0 LPC 18:0 LPC 16:0 LPC 16:0 LPC 16:0 LPC 16:0	Holecular Fo CuDHttyNOsP CzyDHtgNOrP CzyHtgNOrP	Name Annotations Image: Constraint of the second	Internal Standard © Diacylglycerophosphocholines © Monacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines	AQ	Image: Second	King and a second	BS_MS-AI-U BS_MS-AI-U BS_MS-AI-U IJ I IJ I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
6	1 Feat 1 2 3 4 5 6 7 8 9 10 11	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 8.87 2.90	CCS 289.3 235.8 295.3 293.6 298.1 232.1 239.9 229.1 293.8 232.8 298.8 298.8	Mob mS 1.419 1.148 1.448 1.448 1.441 1.128 1.128 1.167 1.115 1.441 1.131 1.462 1.131	igma • 2 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 2.0	ACCS (%) 1.1 0.6 1.0 0.0 0.1 -1.1 0.6 0.3 1.0 0.2	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799 -1.113 -0.127 -0.892 0.127	Δm/z (mD -0.7 -0.5 -0.8 -0.4 -0.3 -0.0 -0.0 -0.7 -0.7	a) m/z meas. 753.61266 529.39963 37 62.60003 49 784.58453 37 772.62063 77 496.34025 59 524.37144 16 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.34018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 520.54018 52	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240 519.33264 783.57698 495.33249 787.60823	filter rules> lons 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0	MS/MS Iks Iks Iks Iks Iks Iks Iks Iks Iks Iks	Name PC LPC PC 34:0 PC 36:3 PC 0-36:2 LPC 16:0 LPC 18:2 PC 36:1 PC 36:1 LPC 18:2 PC 36:1 LPC 16:0 LPC 16:0 LPC 16:0 LPC 16:0	Molecular Fo G.J.DHT,NOLP C.J.DHT,NOLP C.J.DHL,NO.P C.J.HL,NO.P C.	Name Anotations Image: Constraint of the second	nternal Standard O Dacylgiverophosphocholines o Monosylgiverophosphocholines Diacylgiverophosphocholines Diacylgiverophosphocholines Monoacylgiverophosphocholines Diacylgiverophosphocholines Diacylgiverophosphocholines Diacylgiverophosphocholines Diacylgiverophosphocholines	AQ	Image: Second	Image Image <th< td=""><td>D TT 8 DBS_MS-AI-U DBS_MS-AI-U 14 14 25 34 33931, 14 04 0, 25 0, 12, 0, 12, 0, 12, 14</td></th<>	D TT 8 DBS_MS-AI-U DBS_MS-AI-U 14 14 25 34 33931, 14 04 0, 25 0, 12, 0, 12, 0, 12, 14
6	1 1 2 3 4 5 6 7 8 9 10 11 12 12	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 8.87 2.80 9.75	CCS 289.3 235.8 295.3 293.6 298.1 232.1 239.9 229.1 293.8 232.8 298.8 237.7 294.8	Mob mS 1.419 1.148 1.448 1.448 1.441 1.128 1.128 1.167 1.115 1.441 1.131 1.466 1.157	igma • 4 00 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 2.0	ACCS [%] 1.1 0.6 1.0 0.0 0.1 -1.1 0.6 0.3 1.0 0.9 12	Δm/z [ppm] -0.922 -0.699 -1.084 0.704 0.799 -1.113 -0.127 -0.892 -0.133	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.8 -0.0 -0.7 -0.0 -0.7 -0.0	a) m/z meas. 753.61260 529.39963 33 762.60003 19 784.54823 777.2.62063 77 72.62063 79 496.34025 9 524.37144 16 520.34018 3 764.54821 3 496.33970 4 788.61566 0 522.35535 4 97.46750 5 7.66750 5 7.6750 5 7.7500 5 7.75000 5 7.75000 5 7.75000 5 7.75000 5 7.75000 5 7.75000 5 7.75000 5 7.75000 5 7.750000 5 7.750000 5 7.7500	T < M meas. 752.60540 528.39240 761.59297 783.57703 771.61335 495.33240 783.5769 495.33249 787.60823 521.34821 787.60823 521.34821	filter rules> lons 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9	MS/MS ks ks ks ks ks ks ks ks ks	Name PC LPC PC 34:0 PC 36:3 PC 0-36:2 LPC 18:0 LPC 18:0 LPC 18:2 PC 36:3 LPC 18:0 LPC 18:0 LPC 18:1 LPC 18:1	Molecular Fo G.J.DHIJNOJP C.J.DHIJNOJP C.J.HIJNOJP C.J.HIJNOJP C.J.HIJNOJP C.J.HIJNOJP C.J.HIJNOJP	Name Annotations Image: Constraint of the second	P Internal Standard © Diacylglycerophosphocholines o Monacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines		Bit Bit <td>Image Image <th< td=""><td>DES_MS-AI-LU DES_MS-AI-LU DES_MS-AI-LU 14 14 14 339311 14 04 04 04 04 14 04 04 04 14 04 04 04 04 04 04 04 04 04 0</td></th<></td>	Image Image <th< td=""><td>DES_MS-AI-LU DES_MS-AI-LU DES_MS-AI-LU 14 14 14 339311 14 04 04 04 04 14 04 04 04 14 04 04 04 04 04 04 04 04 04 0</td></th<>	DES_MS-AI-LU DES_MS-AI-LU DES_MS-AI-LU 14 14 14 339311 14 04 04 04 04 14 04 04 04 14 04 04 04 04 04 04 04 04 04 0
6	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.81 3.81 2.44 7.14 2.66 8.87 2.80 8.75 7.66	CCS 289.3 235.8 295.3 293.6 298.1 232.1 239.9 229.1 293.8 232.8 232.8 238.8 237.7 294.0	Mob mS 1.419 1.148 1.448 1.441 1.462 1.128 1.167 1.115 1.441 1.466 1.157 1.446 1.442	igma • 4 00 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 3.0 3.0	ACCS (%) 1.1 0.6 1.0 0.0 0.1 -1.1 0.3 1.0 0.9 1.3 0.9	Δm/z [ppm] -0.922 -0.699 -1.084 0.704 0.799 -1.113 -0.127 -0.892 -0.133 -0.975 -0.892	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.8 -0.0 -0.7 -0.0 -0.7 -0.0 -0.7 -0.0	a) m/z meas. 753.61266 529.39963 33 762.60003 39 742.54263 30 772.62063 30 742.5423 31 768.5421 31 496.33970 40 788.61566 32 784.56059 33 768.6059	T M meas.752.60540528.39256761.59297771.61335495.33240523.36380519.33264703.57698704.59392745.59802745.59802767.59892	filter rules> Ions Ions I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0	MS/MS ks ks ks ks ks ks ks ks ks	Name PC IPC PC 34:0 PC 36:3 PC 0-36:2 IPC 18:0 IPC 18:0 IPC 18:1 PC 0-34:1 PC 0-34:1	Current Control C	Name Annotations Image: Ima	nternal Standard O Diacytaycerophosphocholines O Monoacytaycerophosphocholines Diacytaycerophosphocholines Diacytaycerophosphocholines Monoacytaycerophosphocholines Monoacytaycerophosphocholines O Diacytaycerophosphocholines Diacytaycerophosphocholines Diacytaycerophosphocholines Diacytaycerophosphocholines Diacytaycerophosphocholines		Bit Bit <td>Image Image <th< td=""><td>King Service Control Cont</td></th<></td>	Image Image <th< td=""><td>King Service Control Cont</td></th<>	King Service Control Cont
6	1 1 2 3 4 5 6 7 7 8 9 10 11 12 13 14 15	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 8.87 2.80 8.75 7.66 8.75 7.66 5.49	CCS 289.3 235.8 295.3 293.6 298.1 232.9 232.1 239.9 229.1 239.9 229.1 239.8 232.8 237.7 294.8 294.8 294.7	Mob mS 1.419 1.448 1.448 1.448 1.441 1.428 1.128 1.167 1.115 1.441 1.331 1.466 1.157 1.446 1.427	igma 4 2 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 3.0 3.0 3.1	ACCS (%)	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799 -1.113 -0.127 -0.892 -0.133 -0.975 -0.823 -1.224	Δm/z [mE -0.7 -0.5 -0.8 -0.4 -0.4 -0.4 -0.4 -0.4 -0.7 -0.0 -0.7 -0.0 -0.7 -0.6	a) m/z meas. 753.61266 539.3963 33 762.6003 49 764.56453 37 772.62063 59 524.37144 6 520.34016 59 496.34025 59 524.37144 6 520.34016 37 764.5642 30 496.39970 37 766.59953 38 766.59953 39 766.59953	T < M meas. 752.60540 528.39236 761.59297 763.57703 771.61335 495.33240 783.57690 783.57690 783.57690 783.57690 781.568232 745.59902 767.58232	filter rules> Ions 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0	MS/MS ks ks ks ks ks ks ks ks ks ks	Name PC LPC PC 36:3 PC 36:3 PC 16:0 LPC 18:0 LPC 18:2 PC 36:3 LPC 16:0 PC 0:34:1 PC 0:36:4 PC 38:7	Molecular Fou- CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp CarbethinKorp	K Name. Annotations • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • <	Internal Standard Diacylgi yer ophosphocholines Monacylgi yer ophosphocholines Monacylgi yer ophosphocholines Diacylgi yer ophosphocholines Diacylgi yer ophosphocholines Monacylgi yer ophosphocholines		By By<	Image Image <th< td=""><td>KIN 8 KIN 8 K</td></th<>	KIN 8 K
6	1 1 2 3 4 5 6 7 7 8 9 10 111 12 13 14 15 16	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.81 3.46 2.44 7.14 2.66 8.87 2.80 8.75 7.66 5.49 9.03	CCS 289.3 235.8 295.3 293.6 298.1 232.9 239.9 229.1 239.9 229.1 232.8 232.8 232.8 237.7 294.8 237.7 294.8 234.0 290.7 301.1	Mob mS 1.419 1.148 1.441 1.462 1.126 1.167 1.115 1.441 1.131 1.466 1.441 1.131 1.457 1.446 1.427 1.477	igma 4 2 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 3.0 3.0 3.1 3.3	ACCS (%) 1.1 0.6 1.0 0.0 0.1 -1.1 0.6 0.3 1.0 0.9 1.3 0.9 0.3 1.4	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 -0.127 -0.892 -0.133 -0.975 -0.823 -1.224 -0.823	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.0 -0.7 -0.0 -0.7 -0.0 -0.7 -0.6 -0.9 -0.9 -0.4	a) m/z meas. 753.61260 529.39963 30 762.6003 19 784.58453 7772.62063 9 496.34025 9 496.34025 9 524.3714 16 520.34018 704.58421 3 496.3397 44 788.61560 52 2.5535 5 604.55200 33 766.56953 5 774.6367 2 774.6367 2 774.6367	T M meas. 752.60540 528.39236 761.59297 763.57703 771.61335 495.33240 523.36300 519.33264 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 763.576082 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 773.62988 774.7588 774.7588 775.75888 775.75888 775.75888 775	Image: constraint of the second sec	MS/MS ks ks ks ks ks ks ks ks ks ks	Name PC IPC PC 34:0 PC 0-36:3 PC 0-36:2 IPC 16:0 IPC 16:0 PC 36:1 PC 16:0 PC 0-36:1 PC 0-36:4 PC 0-36:4 PC 0-36:4 PC 0-36:4	Molecular Fou- Cap-HH, NO.9 Cap-HH, NO.9 Cap-HH, NO.9 CapHa, NO.	N Name. Annotations V 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <	Internal Standard © Diacylglycerophosphocholines © Monosylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Monosylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines		By But Bar Bar DBS_MS-AI-ULL D 1.000 1.000 1.000 3.166 2.809 0.009 0.899 0.825 0.567 3.262 0.182 1.3431 0.0331 19096.633 19099.633 19099.633 19099.633 19099.633 14314.504 0.071 41886.145 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514 14514	RI RI<	KIN 8 K
6	1 1 2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 8.87 2.80 8.75 7.66 5.49 9.03 8.72	CCS 289.3 235.8 293.6 293.6 298.1 232.1 232.9 229.1 232.8 232.8 232.8 232.8 237.7 294.8 294.0 294.0 290.1 301.1 300.6	Mob mS 1.419 1.148 1.448 1.448 1.442 1.128 1.167 1.115 1.441 1.441 1.442 1.442 1.442 1.442 1.447 1.476	igma - 2 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 3.0 3.0 3.0 3.1 3.3 3.5	ACCS (%) 1.1 0.6 1.0 0.0 0.1 -1.1 0.3 1.0 0.9 0.3 1.4 0.9	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799 -0.127 -0.892 -0.133 -0.975 -0.892 -0.233 -1.224 -0.584 -0.584	Δm/z (mE -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.0 -0.7 -0.0 -0.7 -0.0 -0.7 -0.6 -0.9 -0.4 -0.4	a) m/z meas. 753.61260 529.39963 33 762.6003 99 704.54453 79 496.34025 99 524.37144 777.22.6026 99 524.37144 786.61569 70 522.35535 87 746.60509 33 765.5093 58 004.55280 22 77.4.5667 00 812.61566	T < M meas. 752.60540 528.39236 761.59297 763.57703 771.61335 495.33240 519.33264 783.57609 519.33264 785.57609 521.34821 765.589002 765.589002 776.58232 803.54552 773.62939 811.60879	filter rules> 1005 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	MS/MS hs hs hs hs hs hs hs hs hs hs	Name PC	Molecular Fou- CarloHHMO2P CarloHHMO2P CarloHHMO2P CarloHNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloNO2P CarloN	Name Annotations Image: Constraints Image: Constraints Image: Constraints Image: Constrationts Image: Constraints <t< td=""><td>Diacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines</td><td></td><td>By By By<</td><td>BRI III IIII IIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII</td><td>Image: Second second</td></t<>	Diacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Monacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines Diacylgi verophosphodolines		By By<	BRI III IIII IIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Image: Second
6	1 1 2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 8.87 2.80 8.75 7.66 5.49 9.03 8.72 6.76	CCS 289.3 235.8 295.3 293.6 298.1 232.9 229.1 239.9 229.1 239.9 229.1 232.8 232.8 237.7 294.8 294.0 290.7 301.1 300.6 285.0	Mob mS 1.419 1.148 1.448 1.441 1.442 1.441 1.128 1.167 1.115 1.441 1.131 1.466 1.157 1.446 1.442 1.442 1.447 1.447 1.477 1.476	igma 4 2 00 00 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 3.0 3.0 3.1 3.3 3.5 3.7	ACCS [%] 1.1 0.6 1.0 0.0 0.1 1.1 0.6 0.3 1.0 0.9 1.3 0.9 1.3 0.9 0.3 1.4 0.9 0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799 -1.113 -0.127 -0.992 -0.133 -0.975 -0.623 -1.224 -0.584 -0.584	Δm/z [mE -0.7 -0.5 -0.8 -0.8 -0.0 -0.7 -0.6 -0.7 -0.0 -0.7 -0.6 -0.9 -0.4 -0.7 -0.4 -0.7	a) m/z meas. 753.61266 529.39963 3762.60003 3772.62063 9784.58453 3772.62063 952.437144 16552.34016 3746.61566 752.35535 3766.59953 3766.59953 3766.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 376.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.59953 377.599535 377.59953 377.599535 377.599535 377.599535 377.	T M meas. 752.60540 528.39226 761.59297 771.61335 773.57703 771.61335 783.57703 771.61335 783.57703 771.61335 783.57703 771.61335 783.57032 787.6023 521.34821 745.58902 773.62939 811.60879 731.54591	Image: Second	MS/MS ks ks ks ks ks ks ks ks ks ks	Name PC IPC PC 36:3 IPC 192 PC 36:3 IPC 18:2 PC 18:2 PC 36:1 IPC 18:2 PC 36:3 IPC 18:2 PC 36:3 PC 0-36:1 IPC 0-36:1 PC 0-36:1 P	Molecular Sou. G.,D-HH,NO;P G,D-HH,NO;P G,D-HH,NO;P G,H-H,NO;P G,H-H,NO	N Name Annotations Image: Constraint of the second	Internal Standard © Diacylaylverophosphocholines © Monacylghverophosphocholines Diacylaylverophosphocholines Diacylaylverophosphocholines Monacylghverophosphocholines Monacylghverophosphocholines Diacylghverophosphocholines Diacylghverophosphocholines Diacylghverophosphocholines Diacylghverophosphocholines Diacylghverophosphocholines Diacylghverophosphocholines		Image: Sec: Sec: Sec: Sec: Sec: Sec: Sec: Se	RR RR<	Konstanting Konstanti
6	1 1 2 3 4 5 6 6 7 8 9 10 11 12 13 13 14 15 16 17 18 19	RT [7.32 2.91 8.84 7.38 8.78 2.81 3.46 2.44 7.14 2.66 8.87 2.80 8.75 7.66 5.49 9.03 8.72 6.76 2.30	CCS 289.3 235.8 295.3 295.3 293.6 298.1 232.1 232.8 299.8 232.8 299.8 232.7 294.8 294.0 290.7 301.1 300.6 285.0 285.0	Mob., mS 1.419 1.148 1.448 1.441 1.462 1.128 1.462 1.128 1.415 1.415 1.415 1.441 1.131 1.466 1.427 1.477 1.476 1.397 1.119	igma 4 2 00 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 2.5 3.0 3.0 3.0 3.1 3.3 3.5 3.7 3.8	ACCS [%] 1.1 0.6 1.0 0.0 0.1 -1.1 0.6 1.0 0.3 1.0 0.9 0.3 1.4 0.9 0.3 1.4 0.9 0.3 1.4 0.9 0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Δm/z [ppm] -0.922 -0.699 -1.084 0.799 -1.113 -0.127 -0.992 -0.133 -0.975 -0.823 -1.224 -0.584 -0.569 -0.969 0.075	Δm/z [mC -0.7 -0.5 -0.8 0.4 0.3 0.4 -0.8 -0.9 -0.0 -0.7 -0.0 -0.7 -0.0 -0.7 -0.0 -0.7 -0.0 -0.7 -0.4 -0.7 -0.7 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5	a) m/z meas. 753.61260 529.39963 30 762.60003 97 777.262063 97 94.634025 97 94.634025 97 94.634025 97 94.634025 97 94.63402 97 94.63402 97 94.63402 97 94.63405 98 74.66050 93 766.5995 35 604.55280 20 774.63667 00 812.61568 00 812.61568 01 92.53307 92.033981	T < M meas. 752.60540 528.39236 771.61335 495.33240 523.36380 519.33244 787.60823 521.34821 783.57692 783.57692 783.57692 783.57692 783.57692 783.54591 731.54591 519.33251	Image: Second	MS/MS &s &s &s &s &s &s &s &s &s &s	Name PC LPC PC 36:3 PC 0:36:2 PC 0:36:2 PC 0:36:2 PC 0:36:2 LPC 16:0 PC 36:1 LPC 16:1 PC 0:36:4 PC 0:36:1 PC 0:36:3 PC		N Name Annotations Image: Comparison of the c	20 Internal Standard 0 Diacylglycerophosphotholines 0 Monacylglycerophosphotholines Diacylglycerophosphotholines Monacylglycerophosphotholines Monacylglycerophosphotholines Monacylglycerophosphotholines Monacylglycerophosphotholines Diacylglycerophosphotholines Diacylglycerophosphotholines Diacylglycerophosphotholines Diacylglycerophosphotholines Diacylglycerophosphotholines		Image: Second	R1 R2 R2 85.MS-AI-ULL 0 1.000 1.000 3.168 3.024 40196.512 1.877 0.937 0.622 3.168 0.183 0.033 1.847 0.037 0.622 3.168 0.183 0.035 0.066 9955.051 3.076 0.0495 0.066 0.041 0.084 0.0841 0.084	Image: Second
6	1 1 2 3 4 5 6 6 7 8 9 9 10 11 12 13 14 15 16 17 18 19 20	RT [7.32 2.91 8.84 7.38 8.84 7.38 8.87 2.80 8.75 7.66 8.87 2.80 8.87 2.80 8.75 7.66 8.87 2.80 8.75 2.60 8.549 9.03 8.72 2.30 2.30 2.30	CCS 289.3 235.8 295.3 293.6 298.6 232.1 232.9 232.8 232.8 232.8 237.7 294.8 294.0 294.0 294.0 294.0 294.0 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.7 294.8 294.8 294.7 294.8 294.8 294.7 294.8 294.8 294.8 294.7 294.8 294.8 294.8 294.8 294.8 294.7 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.8 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 294.9 295.9 294.9 295.9 295.7 294.8 295.9 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 295.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.7 205.	Mob., mS 1,419 1,448 1,448 1,444 1,442 1,128 1,414 1,466 1,157 1,414 1,446 1,442 1,427 1,476 1,476 1,397 1,133	igma + 4 00 0.9 1.0 1.2 1.4 1.5 1.6 1.7 2.1 1.4 1.5 3.0 3.0 3.0 3.0 3.0 3.3 3.5 3.7 3.8 4.0	ACCS (%) 1.1 0.6 1.0 0.0 1.1 0.6 0.3 1.0 0.9 1.3 1.0 0.9 0.3 1.4 0.9 0.3 1.4 0.9 0.4 0.9 0.4 -0.7 -1.7	Δm/z [ppm] -0.922 -0.699 -1.084 0.965 0.704 0.799 -1.113 -0.127 -0.892 -0.133 -0.975 -0.823 -1.224 -0.584 -0.584 -0.584 -0.584 -0.584 -0.599 0.075 -0.75	Δm/z [mE -0.7 -0.5 -0.8 0.4 0.3 -0.0 -0.7 -0.0 -0.7 -0.6 -0.9 -0.4 -0.7 -0.7 -0.6 -0.9 -0.4 -0.7 -0.7 -0.7 -0.7 -0.7 -0.7 -0.7 -0.5 -0.8 -0.8 -0.9 -0.7 -0.5 -0.8 -0.8 -0.8 -0.8 -0.8 -0.8 -0.8 -0.8	a) m/z meas. 753.61266 529.39963 37 65.60003 39 764.54053 39 745.45453 30 772.62063 30 784.54021 31 974.540542 31 96.34025 31 96.34025 31 766.50953 31 766.50953 31 766.50953 32 766.50953 32 766.50953 32 766.50953 31 767.50953 31 767.50953	T < M meas. 752.60540 528.39236 761.59297 783.57703 771.61335 495.33240 789.33240 789.53246 789.5052 787.6023 521.34821 745.59802 777.62939 811.60879 731.54591 519.33251	Image: Second	MS/MS &s &s &s &s &s &s &s &s &s &s	Name PC IPC PC 34:0 PC 36:3 PC 0-36:2 IPC 16:0 IPC 18:2 PC 0-36:1 PC 0-34:1 PC 0-34:1 PC 0-34:1 PC 0-34:1 PC 0-34:1 PC 0-36:4 PC 38:7 PC 0-36:1 PC 0	✓ ↓ • Мејсал Го, сдо-Нулор сдо-Нулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сдецулор сде сд	N (Name, Annotations V Image: Constraints V Image: Constraints V Image: Constrate V Image: Constrate V	P Internal Standard © Diacylglycerophosphocholines o Monacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Diacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines Monacylglycerophosphocholines		Image Image <t< td=""><td>R1 R2 R3 <thr3< th=""> R3 R3 R3<!--</td--><td>Image: Second second</td></thr3<></td></t<>	R1 R2 R3 R3 <thr3< th=""> R3 R3 R3<!--</td--><td>Image: Second second</td></thr3<>	Image: Second

Semi-quantitation of lipids in advanced microsamples

The concentrations of measured lipids can be calculated in MetaboScape using a single-point internal standard (ISTD) as a surrogate based on their lipid subclasses as shown in Figure 3. A target list containing the ISTD information such as retention time, molecular formula, working concentration and the compound class was created (Figure 3A). This target list was then used to annotate the Feature Table and the annotated ISTDs are shown with a "T" symbol in the 'Annotation' column (Figure 3B). When an annotated lipid (i.e. PC 36:3) has the same compound class as the ISTD (PC 33:1-d7; Figure 3B - red box), the concentration will be calculated based on the following formula: (peak area (measured)/ peak area (ISTD)) × concentration (ISTD). For lipids that do not have a corresponding ISTD, no concentration is reported (Figure 3B – yellow box).

Here in Figure 4, a t-test was employed and visualized using a volcano plot to identify lipid features that are different (p-value < 0.05, fold change >1.5) between the two groups. A series plot within MetaboScape can also be used to quickly visualize the trajectory of lipid species across sample cohorts. Figure 4B demonstrates how some of the annotated lipid species measured in DBS are changing between non-diabetic and diabetic patient controls.

A lower level of lysophosphatidylcholine (LPC) species were observed in DBS from diabetic patients compared to control subjects. Meanwhile, a higher amount of triacylglycerols (TG) are observed in diabetics compared to controls. These lipid concentrations were further quantitated using its respective ISTD, shown in Table 3. These observations are also similarly reported in another paper suggesting that LPC and TG changes are correlated to obesity-related factors such as diet and adiposity [6] as many of these lipids play important signaling roles with diverse biological function and are involved in regulating cellular proliferation, tumor cell invasion and inflammation.



Figure 4. Statistical analysis in MetaboScape showing lipid variations between control and diabetic individuals. (A) A volcano plot illustrating the lipid abundance between two groups. Lipids that are less abundant in the control group are shown on the left (red), while those less abundant in diabetics are displayed on the right (blue). (B) Series plot showing increases of TG and decreases of LPC, based on relative intensities, between controls and diabetic individuals.

Table 3. DBS lipid concentrations in control and diabetic individuals (n=17). Lipids were quantified using its respective spiked ISTD. Lipids shown have a p-value <0.05.

Lipid Species	Control (µM)	Diabetic (µM)
LPC 14:0	0.99 ± 0.35	0.77 ± 0.24
LPC 16:0	58.15 ± 8.65	43.65 ± 9.13
LPC 18:0	25.84 ± 8.37	17.07 ± 4.39
LPC 18:1	15.43 ± 4.34	11.02 ± 3.74
LPC 18:2	18.84 ± 5.98	13.28 ± 4.97
LPC 20:0	0.20 ± 0.05	0.15 ± 0.04
LPC 20:1	0.27 ± 0.09	0.20 ± 0.07
LPC 20:2	0.18 ± 0.06	0.11 ± 0.04
LPC 20:3	1.21 ± 0.43	0.87 ± 0.32
TG 52:2	57.09 ± 56.29	142.39 ± 95.64
TG 54:3	16.21 ± 14.12	43.09 ± 31.47
TG 56:3	1.14 ± 1.08	3.58 ± 2.75

Conclusions

- In-depth analysis of lipids from dried blood spots using a complete 4D-Lipidomics workflow with timsTOF Pro, RealTime QC and MetaboScape 2025 from sample acquisition, quality checks during data acquisition to lipids identification and quantification respectively.
- Real-time monitoring of data acquisition using RealTime QC provides at-a-glance data visualization
 of selected analytes. Outliers are automatically highlighted for informed decision-making during the
 experiment.
- 4D-Kendrick mass defect plots, together with MetaboScape RT and CCS outlier detection, offers quick visualization and curation of lipid species for higher-confidence annotation.
- Out of the 357 rule-based annotated lipids, 222 lipids were quantitated in DBS based on internal standard normalization of identical lipid class in MetaboScape 2025.

References

- Mikhael A, Hardie D, Smith D, Pětrošová H, Ernst RK, Goodlett DR (2023). Structural Elucidation of Intact Rough-Type Lipopolysaccharides using Field Asymmetric Ion Mobility Spectrometry and Kendrick Mass Defect Plots. Cold Spring Harbor Laboratory.
- [2] Watson AD (2006). Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Lipidomics: a global approach to lipid analysis in biological systems. Journal of Lipid Research 47(10) 2101-2111.
- [3] Kim J, Mun DG, Ding H, Forsberg EM, Meyer SW, Barsch A, Pandey A, Byeon SK (2025). Single Cell Untargeted Lipidomics using Liquid Chromatography Ion Mobility-Mass Spectrometry. Journal of Proteome Research. https://pubs.acs.org/doi/10.1021/acs. jproteome.4c00658
- [4] Roberts JL, Ryan MJ, While L, Gay M, Nambiar V, Holmes E, Nicholson JK, Wist J, Gray N, Lawler NG (2025). Dried blood spot microsampling: A semi-quantitative 4D-Lipidomics approach using ultrahigh-performance liquid chromatography - high-resolution mass spectrometry (UHPLC - HRMS). Talanta 1;287:127677.
- [5] Liebisch G, Fahy E, Aoki J, Dennis EA, Durand T, Ejsing CS, Fedorova M, Feussner I, Griffiths WJ, Köfeler H, Merrill AH, Jr., Murphy RC, O'Donnell VB, Oskolkova O, Subramaniam S, Wakelam MJO, Spener F (2020). Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J Lipid Res 61(12) 1539-1555.
- [6] Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA, Bruce CR. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoSONE 7(7): e41456.

For Research Use Only. Not for use in clinical diagnostic procedures.

Bruker Switzerland AG

Fällanden · Switzerland Phone +41 44 825 91 11

Bruker Scientific LLC

Billerica, MA · USA Phone +1 (978) 663-3660

